273 related articles for article (PubMed ID: 26063327)
1. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study.
Lurie P; Chahal HS; Sigelman DW; Stacy S; Sclar J; Ddamulira B
BMJ; 2015 Jun; 350():h2758. PubMed ID: 26063327
[TBL] [Abstract][Full Text] [Related]
2. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
Chahal HS; Mukherjee S; Sigelman DW; Temple R
JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
[TBL] [Abstract][Full Text] [Related]
3. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
4. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
[TBL] [Abstract][Full Text] [Related]
5. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
Symonds T; Hackford C; Abraham L
Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
[TBL] [Abstract][Full Text] [Related]
6. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
Cowden AL; Katz KA
Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
[TBL] [Abstract][Full Text] [Related]
7. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
Shetty YC; Saiyed AA
J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
[TBL] [Abstract][Full Text] [Related]
8. FDA review divisions: performance levels and the impact on drug sponsors.
Milne CP; Kaitin KI
Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
[TBL] [Abstract][Full Text] [Related]
9. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
10. An Evaluation of US Food and Drug Administration's Program to Register HIV Drugs for Use in Resource-Constrained Settings.
Chahal HS; Koukounas K; Capella P; Presto R; Murray JS; Shimer M; Riley K; Valdez ML
JAMA Netw Open; 2019 Nov; 2(11):e1915787. PubMed ID: 31747034
[TBL] [Abstract][Full Text] [Related]
11. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
12. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
13. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
14. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
15. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
16. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
[TBL] [Abstract][Full Text] [Related]
17. Does Sackett foreshadow the end of non-reviewability for FDA warning letters?
DeRuyter K
Food Drug Law J; 2013; 68(3):241-58, i. PubMed ID: 24640609
[TBL] [Abstract][Full Text] [Related]
18. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
Nicholson S; Peterson J; Yektashenas B
Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
